MCID: PST011
MIFTS: 52

Pustulosis of Palm and Sole

Categories: Skin diseases

Aliases & Classifications for Pustulosis of Palm and Sole

MalaCards integrated aliases for Pustulosis of Palm and Sole:

Name: Pustulosis of Palm and Sole 12 15
Psoriasis 43 71
Pustular Psoriasis of the Palms and/or Soles 12
Acrodermatitis Continua of Hallopeau 71
Generalized Pustular Psoriasis 71
Pustulosis of Palms and Soles 71
Palmoplantar Pustulosis 12
Acropustulosis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4398
MeSH 43 D011565
NCIt 49 C34888
SNOMED-CT 67 27520001
ICD10 32 L40.3
UMLS 71 C0030246 C0033860 C0343055 more

Summaries for Pustulosis of Palm and Sole

MalaCards based summary : Pustulosis of Palm and Sole, also known as psoriasis, is related to impetigo herpetiformis and psoriasis 14, pustular, and has symptoms including pruritus, exanthema and psoriasiform rash. An important gene associated with Pustulosis of Palm and Sole is CCR6 (C-C Motif Chemokine Receptor 6), and among its related pathways/superpathways are PEDF Induced Signaling and Cytokine Signaling in Immune system. The drugs Esomeprazole and Dapsone have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and testes, and related phenotypes are hematopoietic system and immune system

Related Diseases for Pustulosis of Palm and Sole

Diseases related to Pustulosis of Palm and Sole via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1331)
# Related Disease Score Top Affiliating Genes
1 impetigo herpetiformis 33.1 IL36RN IL1RL2 CARD14
2 psoriasis 14, pustular 33.0 IL36RN AP1S3
3 pustular psoriasis 32.9 TNF IL36RN AP1S3
4 geographic tongue 32.8 IL36RN IL1RL2 CARD14
5 pustulosis palmaris et plantaris 32.4 TNF IL36RN CCR6 AP1S3
6 systemic onset juvenile idiopathic arthritis 32.3 TNF IL1RN
7 chickenpox 30.7 TNFRSF1B TNF CCR6
8 necrobiosis lipoidica 30.6 TNFRSF1B TNF
9 enthesopathy 30.6 TNFRSF1B TNF MRAP CCR6
10 syphilis 30.5 MRAP IL17A CCR6
11 nail disease 30.5 TNFRSF1B TNF IL17A CCR6
12 cutaneous candidiasis 30.5 IL17A CCR6
13 tenosynovitis 30.4 TNFRSF1B TNF MRAP
14 synovitis 30.4 TNF IL1RN CXCL8
15 nasopharyngitis 30.4 TNFRSF1B TNF IL17A
16 lichen planus 30.4 TNF IL17A CXCL8
17 rheumatic disease 30.3 TNFRSF1B TNF IL1RN CCR6
18 rosacea 30.3 TNF CXCL8 CCR6
19 crohn's colitis 30.3 TNF CXCL8 CCR6
20 skin sarcoidosis 30.3 TNFRSF1B TNF
21 histoplasmosis 30.3 TNFRSF1B TNF CCR6
22 spondylitis 30.2 TNFRSF1B TNF IL1RN IL17A CCR6
23 acute generalized exanthematous pustulosis 30.2 IL36RN IL17A CXCL8
24 acquired immunodeficiency syndrome 30.2 TNFRSF1B TNF CCR6
25 ankylosis 30.1 TNFRSF1B TNF MRAP CCR6
26 sarcoidosis 1 30.1 TNFRSF1B TNF MRAP IL1RN CCR6
27 allergic contact dermatitis 30.1 TNF IL17A CXCL8
28 acrodermatitis 30.1 TNFRSF1B IL36RN IL1RL2 CARD14 AP1S3
29 childhood type dermatomyositis 30.0 TNFRSF1B TNF CCR6
30 bursitis 30.0 TNFRSF1B TNF MRAP
31 iridocyclitis 30.0 TNFRSF1B TNF MRAP IL17A
32 alopecia areata 30.0 TNF IL1RN IL17A
33 leukemia, acute monocytic 30.0 TNF SIGLEC5 CXCL8
34 iritis 30.0 TNFRSF1B TNF MRAP CCR6
35 neurofibromatosis, type ii 29.9 TNF SIGLEC5 IL1RN CXCL8 CCR6
36 meningitis 29.9 TNF IL17A CXCL8
37 posterior uveitis 29.9 TNF MRAP CCR6
38 tendinitis 29.9 TNFRSF1B TNF MRAP
39 chlamydia 29.9 TNF IL17A CXCL8
40 dermatitis 29.9 TNF IL17A CXCL8 CCR6
41 blepharitis 29.9 TNF CXCL8 CCR6
42 osteomyelitis 29.9 TNF LPIN2 IL1RN CXCL8
43 posterior scleritis 29.9 TNF MRAP
44 leprosy 3 29.8 TNF IL17A CXCL8 CCR6
45 candidiasis 29.8 TNF IL17A CXCL8
46 retinal vasculitis 29.8 TNFRSF1B MRAP CCR6
47 pharyngitis 29.8 TNFRSF1B TNF IL1RN CXCL8
48 mycobacterium tuberculosis 1 29.8 TNFRSF1B TNF IL17A CCR6
49 spondyloarthropathy 1 29.8 TNFRSF1B TNF MRAP IL1RN IL17A CCR6
50 nocardiosis 29.8 TNFRSF1B TNF

Graphical network of the top 20 diseases related to Pustulosis of Palm and Sole:



Diseases related to Pustulosis of Palm and Sole

Symptoms & Phenotypes for Pustulosis of Palm and Sole

UMLS symptoms related to Pustulosis of Palm and Sole:


pruritus, exanthema, psoriasiform rash

MGI Mouse Phenotypes related to Pustulosis of Palm and Sole:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.85 CCR6 GPRIN1 IL17A IL1RL2 IL1RN IL36RN
2 immune system MP:0005387 9.7 CARD14 CCR6 GPRIN1 IL17A IL1RL2 IL1RN
3 integument MP:0010771 9.23 CARD14 IL17A IL1RL2 IL1RN IL36RN PSTPIP2

Drugs & Therapeutics for Pustulosis of Palm and Sole

Drugs for Pustulosis of Palm and Sole (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 459)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
2
Dapsone Approved, Investigational Phase 4 80-08-0 2955
3
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 32798 5311051
4
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
5
Clocortolone Approved Phase 4 4828-27-7, 34097-16-0 5282493 5311052
6
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
7
Sodium citrate Approved, Investigational Phase 4 68-04-2
8
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
9
carbamide peroxide Approved Phase 4 124-43-6
10 Orange Approved Phase 4
11 Artichoke Approved Phase 4
12 Strawberry Approved Phase 4
13
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
14 Brodalumab Approved, Investigational Phase 4 1174395-19-7
15
Adalimumab Approved Phase 4 331731-18-1 16219006
16
Certolizumab pegol Approved Phase 4 428863-50-7
17
Desoximetasone Approved Phase 4 382-67-2 5311067
18
Abatacept Approved Phase 4 332348-12-6 10237
19
Tofacitinib Approved, Investigational Phase 4 477600-75-2
20
Zinc Approved, Investigational Phase 4 7440-66-6 32051
21
Mercaptopurine Approved Phase 4 50-44-2 667490
22
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
23
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
24 Ixekizumab Approved, Investigational Phase 4 1143503-69-8
25
Ustekinumab Approved, Investigational Phase 4 815610-63-0
26
Metformin Approved Phase 4 657-24-9 14219 4091
27 Vedolizumab Approved Phase 4 943609-66-3
28
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
29
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
30
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
31
Capsaicin Approved Phase 4 404-86-4 1548943
32
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4, 22737-96-8 445354 9904001
33
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
34
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
35
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
36
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 134070 5280453
37 retinol Phase 4
38 Retinol palmitate Phase 4
39 Antiparasitic Agents Phase 4
40 Antiprotozoal Agents Phase 4
41 Antimalarials Phase 4
42 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
43 Tin Fluorides Phase 4
44 Immunoglobulin A Phase 4
45
Chondroitin Phase 4 9007-27-6 53477707
46 Halobetasol Phase 4
47 Clocortolone pivalate Phase 4
48 Olive Phase 4
49 Omega 3 Fatty Acid Phase 4
50 Chlorpheniramine, phenylpropanolamine drug combination Phase 4

Interventional clinical trials:

(show top 50) (show all 1611)
# Name Status NCT ID Phase Drugs
1 Improvement in the Quality of Life of Patients With Severe Plaque Psoriasis Treated With Systemic Methotrexate in Fixed Doses of 10mg or 25mg Orally Once Weekly: a Prospective, Randomized, Double-blind, Parallel Group Study. Unknown status NCT02248792 Phase 4 Methotrexate
2 A Phase4,Multicenter, Randomized,Double-blind,Double Dummy, Parallel Controlled Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Treatment of Chinese Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01443338 Phase 4 Triptergium Wilfordii;Acitretin
3 The Difference of Circulating Endothelial-derived and Platelet-derived Microparticles in Patients With Psoriasis Successfully Treated With Stelara(Ustekinumab) Unknown status NCT02693470 Phase 4 Ustekinumab
4 Proton Pump Inhibitors Use in Patients With Psoriasis Unknown status NCT02624544 Phase 4 esomeprazole;desonide
5 Phase IV Study on Efficacy and Safety of the Combination Treatment Acitretin and Efalizumab in Moderate to Severe Chronic Plaque Psoriasis Unknown status NCT00707070 Phase 4 efalizumab plus placebo;efalizumab plus acitretin
6 Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic: Nail Disease a Single-blind, Intrapatient Left-to-right Controlled Study. Unknown status NCT03263624 Phase 4 Tazarotene Cream 0.1%
7 An Open Label Trial to Show That Subjects With Severe Plaque-Type Psoriasis Receiving Acitretin 25 mg/Day And Stabilized On A Photochemotherapy Regimen Who Are Experiencing Retinoid-Related Adverse Events, Benefit From A Reduction In Acitretin Dose to 17.5 mg/Day, While Maintaining Comparable Efficacy Along With Improved Tolerability Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
8 An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use Unknown status NCT01132235 Phase 4
9 The Influence of Adalimumab vs. Fumaric Acid Esters on Cardiovascular and Metabolic Risk Factors in the Therapy of Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01088165 Phase 4 Adalimumab treatment arm;Fumaric acid esters treatment group
10 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis: a Randomized, Investigator-blinded Study Unknown status NCT01439425 Phase 4
11 A Double - Blind, Placebo Controlled Crossover Study to Evaluate The Efficacy and Tolerability of Stelara ™ (Ustekinumab) in The Treatment of Scalp Psoriasis Unknown status NCT01558310 Phase 4 Ustekinumab;Placebo
12 Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After Adalimumab Therapy Unknown status NCT01237262 Phase 4 Adalimumab, etanercept, infliximab
13 Home UVB Phototherapy for Psoriasis: Effectiveness, Quality of Life and Cost-Effectiveness Unknown status NCT00150930 Phase 4
14 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Comparison With Tuberculin Skin Test in Patients With Psoriasis and Psoriatic Arthritis Unknown status NCT01223976 Phase 4
15 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
16 The Effect of Vitamin A Supplementation on CD4+ T-cell Secretion in Obese Individuals Unknown status NCT01405352 Phase 4
17 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Etanercept in Treating Scalp Involvement in Subjects With Moderate to Severe Plaque Psoriasis Completed NCT00791765 Phase 4
18 A Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etanercept in the Treatment of Subjects With Psoriasis Completed NCT00195507 Phase 4 Etanercept
19 Canadian Assessment of Patient Outcomes and Effectiveness of Enbrel (Etanercept) in Psoriasis Completed NCT00332332 Phase 4
20 A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly and Etanercept 50 mg Once Weekly for the Treatment of Moderate to Severe Psoriasis Completed NCT00663052 Phase 4 Etanercept;Etanercept
21 Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05% Completed NCT01893567 Phase 4 Clobex Spray
22 A Multicenter, Open-label, Randomized, Pilot-study to Evaluate the Efficacy and Safety of the Combination of Etanercept (ETN) and Methotrexate and of Etanercept (ETN) Alone in Patients With Plaque Psoriasis Despite Methotrexate Therapy Completed NCT00161655 Phase 4 Etanercept;Methotrexate
23 An Open-Label Phase 4 Study in Adult Patients With Chronic Plaque Psoriasis to Evaluate the Immune Response to Pneumococcal Vaccine in Subjects Treated With Alefacept Completed NCT00493324 Phase 4 alefacept;polyvalent pneumococcal vaccine
24 Optimizing Psoriasis Treatment of Etanercept Combined Methotrexate: a Phase IV, Multicenter, Randomized, Double-blind, Controlled Trial Completed NCT02313922 Phase 4 etanercept combined with methotrexate or etanercept combined with placebo
25 A Randomized Pilot Study Evaluating the Efficacy and Safety of Etanercept in Patients With Moderate to Severe Plaque Psoriasis After Cessation of Ciclosporin Therapy Completed NCT00581555 Phase 4 Etanercept
26 An Extension Study of Brodalumab in Subjects With Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic Erythroderma Completed NCT04183881 Phase 4 Brodalumab 210mg SC
27 Elocon vs Fluticasone in Localized Psoriasis Completed NCT00763529 Phase 4 Mometasone;Fluticasone
28 Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population Completed NCT02533973 Phase 4 Xamiol® gel;Daivonex® scalp solution
29 Fase IV Clinical Trial to Evaluate Chondroitin Sulphate Efficacy and Safety in Patients With Knee Osteoarthritis and Psoriasis Completed NCT00669123 Phase 4 Chondroitin sulphate;Placebo
30 Evaluating Safety in Patients With Moderate to Severe Psoriasis Treated With Etanercept Completed NCT00581165 Phase 4 Etanercept
31 A Randomised, Double-Blind, Active-Controlled, Parallel, Multi-Center Study to Investigate the Efficacy and Safety of Daivobet® Ointment in Patients With Psoriasis Vulgaris Completed NCT00248456 Phase 4 Calcipotriol plus betamethasone dipropionate ointment
32 A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Completed NCT00287118 Phase 4 Efalizumab
33 An Open-Label, Study Evaluating Topicort® Topical Spray 0.25% (Desoximetasone) in Patients With Scalp Psoriasis Completed NCT02985736 Phase 4 Topicort Topical Spray
34 An Open-Label, Multicenter Study of the Efficacy of Cloderm® Cream (Clocortolone Pivalate, 0.1%) in the Treatment of Moderate Plaque Psoriasis for 28 Days Completed NCT01714544 Phase 4 Cloderm Cream
35 Efficacy and Safety of Alefacept in Combination With Narrow-band UVB (nbUVB) Compared to Alefacept Alone in Subjects With Moderate to Severe Chronic Plaque Psoriasis Completed NCT00658606 Phase 4 alefacept
36 Safety and Efficacy of Etanercept in Patients With Moderate to Severe Plaque Psoriasis Who Have Shown an Unsatisfactory Response to Adalimumab or Infliximab Completed NCT00967538 Phase 4 etanercept 50 mg
37 A Trial That Compound Clobetasol Propionate Ointment Treats Patients With Mild to Moderate Psoriasis Vulgaris. Completed NCT02733874 Phase 4 Compound Clobetasol Propionate Ointment;Calcipotriol Betamethasone Ointment
38 A Study to Evaluate the Efficacy and Tolerability of Clobetasol Propionate vs. Vehicle in the Treatment of Mild to Moderate Plaque-Type Psoriasis Completed NCT00842153 Phase 4 Clobetasol propionate foam;Vehicle foam
39 A Single-Center, Open-Label Study to Assess Change in Psychosocial and Occupational Dimensions With Ustekinumab Treatment of Moderate-to-Severe Psoriasis Evaluated With the Psychological General Well Being (PGWB), Work Productivity and Activity Impairment (WPAI), Psoriasis Quality of Life-12 Items (PQOL-12), and Dermatology Life Quality Index (DLQI) Completed NCT01511315 Phase 4 Ustekinumab
40 An Open Label, Non-comparative, Multicentre, Phase IV Study to Evaluate the Safety, Tolerability and Efficacy of Tinefcon in Patients With Plaque Psoriasis Completed NCT01373567 Phase 4 TINEFCON
41 A Multicenter, Open-Label, Pilot Trial to Evaluate the Effectiveness and Safety of ENBREL(r) in Combination With Narrowband UVB Phototherapy for the Treatment of Psoriasis Completed NCT00110981 Phase 4 Etanerept;Etanercept
42 A Single-arm Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Subjects With Plaque Psoriasis Completed NCT02274792 Phase 4 Etanercept
43 A PHASE IV, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF USTEKINUMAB ON VASCULAR INFLAMMATION IN PSORIASIS Completed NCT02187172 Phase 4 Ustekinumab;Placebo
44 A Study to Evaluate Safety and Efficacy of Clobetasol Propionate for Treatment of Plaque-Type Psoriasis in Adult Subjects. Completed NCT00852761 Phase 4 Olux-E Foam;Clobex lotion
45 Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast Completed NCT02749370 Phase 4 Etanercept
46 An Evaluation of the Efficacy, Safety, Preference and Duration of Response of Clobex® (Clobetasol Propionate) Spray and Taclonex® (Calcipotriene 0.05%/Betamethasone Dipropionate 0.064%) Ointment in Subjects With Stable Plaque Psoriasis Completed NCT00437255 Phase 4 Clobetasol Propionate, 0.05%;Calcipotriene and betamethasone dipropionate ointment
47 A Comparison Between Clobetasol Propionate (Clobex®) Spray and Clobetasol Propionate (Olux®) Foam With Regard to Efficacy, Safety, Preference and Duration of Response in Stable Plaque Psoriasis Completed NCT00436540 Phase 4 Clobetasol Propionate 0.05% Spray;Clobetasol Propionate 0.05% Foam
48 Pharmacokinetics and Pharmacodynamics of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 14 Days Under Conditions of Maximal Use in Pediatric Subjects (2 to 12 Years of Age) With Plaque Psoriasis Completed NCT01766440 Phase 4 Calcitriol 3 mcg/g ointment
49 A Phase 4 Study to Assess the Practical Management of Mild to Moderate Arthritic or Arthralgic Events in Patients With Chronic Plaque Psoriasis Receiving Efalizumab Completed NCT00510536 Phase 4 Acetaminophen;NSAID
50 Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice Completed NCT01147874 Phase 4

Search NIH Clinical Center for Pustulosis of Palm and Sole

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Acitretin
alefacept
Aloe vera preparation
Anthralin
ANTHRALIN PWDR
Betamethasone
Betamethasone acetate
Betamethasone benzoate
betamethasone dipropionate
betamethasone sodium phosphate
Betamethasone valerate
BETAMETHASONE VALERATE PWDR
calcipotriene
Calcitriol
Cholecalciferol
Coal Tar
Coal tar extract
Coal tar pitch volatiles
COAL TAR,COLLOIDAL
COAL TAR,REFINED
Cod Liver Oil
Colloid sulfur
Cyclosporine
Etretinate
Fish Liver Oils
fluocinolone
Fluocinolone Acetonide
hydroxyurea
Methotrexate
Methotrexate Sodium
Methoxsalen
mycophenolate mofetil
mycophenolate mofetil hydrochloride
Salicylic Acid
SALICYLIC ACID PWDR
Sulfur
SULFUR PWDR
SULFUR,COLLOIDAL
tazarotene
Thioguanine
Trioxsalen

Cochrane evidence based reviews: psoriasis

Genetic Tests for Pustulosis of Palm and Sole

Anatomical Context for Pustulosis of Palm and Sole

MalaCards organs/tissues related to Pustulosis of Palm and Sole:

40
Skin, T Cells, Testes, Liver, Neutrophil, Bone, Endothelial

Publications for Pustulosis of Palm and Sole

Articles related to Pustulosis of Palm and Sole:

(show top 50) (show all 30000)
# Title Authors PMID Year
1
Hydrogen peroxide in neutrophil inflammation: Lesson from the zebrafish. 61
31862296 2020
2
Pruritus and sleep disturbances in patients with psoriasis. 61
31616971 2020
3
In vitro evaluation of Naltrexone HCl 1% Topical Cream in XemaTop™ for psoriasis. 61
31667579 2020
4
CARD14/CARMA2sh and TANK differentially regulate poly(I:C)-induced inflammatory reaction in keratinocytes. 61
31486084 2020
5
Off-label studies on apremilast in dermatology: a review. 61
30935262 2020
6
Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study. 61
30887876 2020
7
Antibodies towards high-density lipoprotein components in patients with psoriasis. 61
31612328 2020
8
Biological therapy for pustular psoriasis: a systematic review. 61
31612467 2020
9
Our ambition in a changing landscape of psoriasis treatments. 61
31903808 2020
10
Preparation, characterization, and in vivo evaluation of cyclosporine cationic liposomes for the treatment of psoriasis. 61
30897993 2020
11
Taxifolin attenuates IMQ-induced murine psoriasis-like dermatitis by regulating T helper cell responses via Notch1 and JAK2/STAT3 signal pathways. 61
31881484 2020
12
Patients preferences for different corticosteroid vehicles are highly variable. 61
29770722 2020
13
EFLA 945 restricts AIM2 inflammasome activation by preventing DNA entry for psoriasis treatment. 61
31837587 2020
14
Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial. 61
30799638 2020
15
Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial. 61
31175909 2020
16
Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2). 61
31563641 2020
17
Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis. 61
31917928 2020
18
Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis. 61
31672774 2020
19
Measurement properties of instruments assessing psoriatic arthritis symptoms for psoriasis clinical trials: a systematic literature review. 61
32037912 2020
20
Declining levels of serum CXCL10 over time are associated with new onset of psoriatic arthritis in patients with psoriasis: A new biomarker? 61
32037514 2020
21
Chronic Stress-Related Neural Activity Associates With Subclinical Cardiovascular Disease in Psoriasis: A Prospective Cohort Study. 61
30448131 2020
22
Safety considerations with combination therapies for psoriasis. 61
31985309 2020
23
Mechanism of danshensu-induced inhibition of abnormal epidermal proliferation in psoriasis. 61
31866405 2020
24
Autophagy-based unconventional secretion of HMGB1 by keratinocytes plays a pivotal role in psoriatic skin inflammation. 61
32019420 2020
25
TRIM27 promotes IL-6-induced proliferation and inflammation factor production by activating STAT3 signaling in HaCaT cells. 61
31747314 2020
26
Neurotransmitters, neuropeptides and their receptors interact with immune response in healthy and psoriatic skin. 61
31902596 2020
27
Changes in serum TNF-like weak inducer of apoptosis (TWEAK) levels and Psoriasis Area Severity Index (PASI) scores in plaque psoriasis patients treated with conventional versus anti-TNF treatments. 61
31531981 2020
28
Persistence with biological drugs in psoriasis patients followed in dermatology practices in Germany: A retrospective cohort study of 1,201 patients
. 61
31670655 2020
29
Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: A double-blind, randomized, vehicle-controlled trial. 61
31279028 2020
30
Correction to: Cell adhesion molecules, plasminogen activator inhibitor type 1, and metabolic syndrome in patients with psoriasis. 61
31915953 2020
31
JAAD Game Changers∗: Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: Results from the Italian Psocare Registry. 61
31574275 2020
32
Secukinumab is effective in treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and safety from the PROSPECT study. 61
31541554 2020
33
Use of topical calcipotriol for identification of patients with psoriasis in administrative healthcare data-a validation study. 61
31574175 2020
34
Secukinumab for patients with plaque psoriasis affected by multiple sclerosis: a mini-review with a representative case report. 61
31667904 2020
35
Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. 61
31102257 2020
36
Exposure-Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients. 61
31355921 2020
37
Meta-Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority. 61
31502263 2020
38
Systemic Treatment of Psoriasis with JAK Inhibitors: A Review. 61
31893355 2020
39
Treatment of Medicare Patients with Moderate-to-Severe Psoriasis who Cannot Afford Biologics or Apremilast. 61
31452091 2020
40
Thyroid dysfunction in patients with psoriasis: Higher prevalence of thyroid dysfunction in patients with generalized pustular psoriasis. 61
31803954 2020
41
Clinical response correlates with 4-week postinjection ustekinumab concentrations in patients with moderate-to-severe psoriasis. 61
31004510 2020
42
Palmoplantar Pustulosis: Recent Advances in Etiopathogenesis and Emerging Treatments. 61
32008176 2020
43
Acitretin inhibits IL-17A-induced IL-36 expression in keratinocytes by down-regulating IκBζ. 61
31863918 2020
44
Zika, chikungunya, and dengue infections as exacerbating factors of psoriasis in patients receiving biological therapy. 61
32039473 2020
45
Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents. 61
31721107 2020
46
Mediation of Adverse Pregnancy Outcomes in Autoimmune Conditions by Pregnancy Complications: A Mediation Analysis of Autoimmune Conditions and Adverse Pregnancy Outcomes. 61
31373768 2020
47
Efficacy and Safety of Apremilast in Patients With Moderate to Severe Plaque Psoriasis of the Scalp: Results of a Phase 3b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study. 61
32032692 2020
48
Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study. 61
31408686 2020
49
JAAD Game Changers∗: Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature. 61
31574273 2020
50
Interrupting tocilizumab therapy-induced psoriasis-like eruption in a patient with rheumatoid arthritis and Crohn's disease. 61
32034760 2020

Variations for Pustulosis of Palm and Sole

Expression for Pustulosis of Palm and Sole

Search GEO for disease gene expression data for Pustulosis of Palm and Sole.

Pathways for Pustulosis of Palm and Sole

Pathways related to Pustulosis of Palm and Sole according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.31 TNFRSF1B TNF IL36RN IL1RN IL1RL2 IL17A
2
Show member pathways
13.08 TNFRSF1B TNF IL1RN IL1RL2 IL17A CXCL8
3 12.29 TNFRSF1B TNF IL1RN IL17A
4
Show member pathways
11.89 TNFRSF1B TNF CXCL8 CCR6
5 11.64 TNF CXCL8 CARD14
6
Show member pathways
11.6 TNF IL36RN IL1RN IL1RL2 CXCL8
7 11.58 TNF IL17A CXCL8
8 11.51 TNFRSF1B TNF IL17A CXCL8
9 11.48 TNF IL17A CCR6
10 11.35 TNF IL1RN IL17A
11 10.79 TNF CXCL8
12 10.61 TNFRSF1B TNF IL1RN CXCL8

GO Terms for Pustulosis of Palm and Sole

Biological processes related to Pustulosis of Palm and Sole according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular response to lipopolysaccharide GO:0071222 9.72 TNFRSF1B TNF IL36RN IL1RN CXCL8
2 immune response GO:0006955 9.7 TNFRSF1B TNF IL36RN IL1RN IL17A CXCL8
3 tumor necrosis factor-mediated signaling pathway GO:0033209 9.63 TNFRSF1B TNF CARD14
4 positive regulation of JNK cascade GO:0046330 9.58 TNF IL36RN IL1RN
5 positive regulation of interleukin-6 production GO:0032755 9.56 TNF IL36RN IL1RN IL1RL2
6 neutrophil chemotaxis GO:0030593 9.54 IL36RN IL1RN CXCL8
7 inflammatory response GO:0006954 9.5 TNFRSF1B TNF IL36RN IL1RN IL1RL2 IL17A
8 embryonic digestive tract development GO:0048566 9.48 TNF CXCL8
9 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.43 TNFRSF1B TNF
10 cytokine-mediated signaling pathway GO:0019221 9.17 TNFRSF1B TNF IL36RN IL1RN IL1RL2 IL17A

Molecular functions related to Pustulosis of Palm and Sole according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 interleukin-1 receptor binding GO:0005149 9.16 IL36RN IL1RN
2 cytokine activity GO:0005125 9.02 TNF IL36RN IL1RN IL17A CXCL8
3 interleukin-1 receptor antagonist activity GO:0005152 8.96 IL36RN IL1RN

Sources for Pustulosis of Palm and Sole

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....